Return to Listing

19 result(s) for

PI Name Protocol # Title
Zahi Mitri IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Gina Vaccaro STUDY00015495 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Raymond Bergan STUDY00015588 Serial Measurements of Molecular and Architectural Responses to Therapy
Prakash Ambady STUDY00016046 Response Assessment to Pembrolizumab with Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging– A Pilot Study
Jacqueline Vuky STUDY00016506 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
Prakash Ambady STUDY00016709 The use of perfusion MRI using ferumoxytol and small molecular weight gadolinium (Gd) agents to assess response to pembrolizumab in brain metastases and systemic lesions in NSCLC: A comparison of imaging modalities to address brain metastases, pseudoprogression and systemic lesion tumor flare (neuro-check pilot)
Zahi Mitri STUDY00017461 [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Jeremy Cetnar STUDY00017753 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Adel Kardosh STUDY00019185 Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)
Dale Han STUDY00019285 A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Jeremy Cetnar STUDY00019330 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
Jacqueline Vuky STUDY00019408 A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Julie Graff STUDY00019558 A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Aimee Kohn STUDY00019679 ADJUVANT THERAPY WITH PEMBROLIZUMAB VERSUS PLACEBO IN RESECTED HIGHRISK STAGE II MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY (KEYNOTE 716)
Julie Graff STUDY00019692 A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Aimee Kohn STUDY00019746 A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
Matthew Taylor STUDY00019829 [NCI CIRB] EA6174: A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Aimee Kohn STUDY00019943 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
Jeremy Cetnar STUDY00020077 [NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080